<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-C2IGV1OI</identifier><date>2022</date><creator>Janić, Miodrag</creator><creator>Volčanšek, Špela</creator><relation>documents/doc/C/URN_NBN_SI_doc-C2IGV1OI_001.pdf</relation><relation>documents/doc/C/URN_NBN_SI_doc-C2IGV1OI_001.txt</relation><format format_type="issue">2</format><format format_type="volume">73</format><format format_type="type">article</format><format format_type="extent">str. 129-136</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">108736515</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-C2IGV1OI</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">antihiperglikemična zdravila</subject><subject language_type_id="slv">cepljenje</subject><subject language_type_id="slv">covid-19</subject><subject language_type_id="slv">imunometabolizem</subject><subject language_type_id="slv">sladkorna bolezen</subject><title>Diabetes and covid-19: syndemic or just casual bystanders</title><title>Sladkorna bolezen in covid-19: sindemija ali le medsebojna opazovalca</title></Record>